Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

OpenBench : and HemoShear Therapeutics Agree to Pursue Rare Disease Target Using Artificial Intelligence

10/05/2021 | 12:22pm EST

SAN FRANCISCO, Oct. 5, 2021 /PRNewswire/ -- OpenBench, Inc., an emerging leader in AI-enabled small molecule discovery, entered into an agreement with HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, to use the OpenBench virtual screening platform to identify novel, potent inhibitors of an undisclosed rare disease target.

Under the terms of the agreement, OpenBench will receive payment for successful identification and experimental confirmation of novel chemotypes that meet HemoShear's potency and developability criteria. In exchange, HemoShear gains exclusive access to OpenBench's proprietary screening technology vis-á-vis its rare disease target of interest. Financial terms were not disclosed.

"We are excited to support HemoShear's efforts to identify clinically relevant therapeutic candidates for a rare disease with significant unmet patient need," said OpenBench CTO James Yoder. "We feel confident that the OpenBench technology will pair nicely with the HemoShear REVEAL-Tx™ platform to help identify potent, developable hits and optimize the likelihood of success for this HemoShear discovery program."

OpenBench adds HemoShear to a growing list of partners that includes one private and two public US-based biotechnology companies.

About OpenBench
OpenBench, Inc. is a private, venture-backed virtual screening platform that partners with small molecule biotechnology companies to enrich preclinical discovery. OpenBench specializes in hit discovery against structurally-enabled disease targets, offering a results-driven solution whereby OpenBench partners only pay after Hit material has been experimentally confirmed to meet potency and developability criteria. OpenBench is currently engaged in four industry partnerships and two academic collaborations across a range of therapeutic areas. To learn more, contact OpenBench at discovery@opnbnch.com or visit https://www.opnbnch.com to sign up for a hit discovery consultation.

Media Contact:
James Yoder

View original content:https://www.prnewswire.com/news-releases/openbench-and-hemoshear-therapeutics-agree-to-pursue-rare-disease-target-using-artificial-intelligence-301392455.html

SOURCE OpenBench

ę PRNewswire 2021
Latest news "Companies"
05:59pWebster Financial Corporation Declares Common and Preferred Dividends
05:57pALERT : Rowley Law PLLC is Investigating Proposed Acquisition of Activision Blizzard Inc.
05:57pEllington Financial Announces Estimated Book Value Per Common Share as of December 31, 2021
05:57pBHP Metallurgical Coal Operations Disrupted by Australia Covid-19 Surge -- Update
05:56pBoston Properties Announces 2021 Tax Treatment of Its Distributions
05:56ponsemi to Announce Fourth Quarter and 2021 Annual Financial Results
05:56pNOVA MINERALS LIMITED (ASX : NVA) Geophysics Confirms Extension of RPM High-Grade Gold Deposit
05:55pSilver Spike Investment Corp. Announces Proposed Initial Public Offering
05:53pVintage Energy Ltd Share Purchase Plan Completed
05:52pYOJEE : Quarterly Activities Report & Appendix 4C - Dec 2021
Latest news "Companies"